Atherosclerosis and Hyperlipidemia

Mohammed Sallam , Hossameldin Hassan , Derek Connolly , et al

Read time: 15m 34s
ESC 24: Day 4 Wrap-Up with Dr Alasnag and Dr Al-Shaibi

Mirvat Alasnag, Khaled Al-Shaibi

Watch time: 15m 45s

Khaled A Shams , Hossameldin Hussein , Soha Romeih , et al

Read time: 5m
PURSUIT: AZD0780 in Patients With Dyslipidaemia

Matthew Roe

Watch time: 7m 7s
ACC.24: Olezarsen for Hypertriglyceridemia and ASCVD

Brian Bergmark

Watch time: 3m 40s
ACC.24: The LIBerate-CVD Trial

Evan A Stein

Watch time: 7m 18s

Nicolas M Van Mieghem, Joost Daemen

Watch time: 1h 35m 42s (16 videos)
ESC 23: LIBerate-HeFH Study

Frederick Raal

Watch time: 4m 16s
ESC 23: OCEAN(a)-DOSE Trial Update

Michelle O'Donoghue

Watch time: 3m 22s

Joost Daemen, Allen Jeremias, Ziad A Ali et al

Watch time: 55m 46s (1 video)

Lale Tokgözoğlu, Kausik Ray, Ulrich Laufs, et al

Watch time: 1h 23m 3s (5 videos)

Julia Brandts

Watch time: 1m 43s

Heather Currie , Christine Williams

Read time: 10m

Jean-Claude Tardif

Watch time: 1h 4m 5s (13 videos)

Edward T Carreras , Donna M Polk

Hans-Willi Breuer

FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano

Watch time: 2m 56s

Lale Tokgözoğlu, Kausik Ray, Ulrich Laufs, et al

Watch time: 1h 23m 3s (5 videos)
FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

Michelle O'Donoghue

Watch time: 3m 30s

Sergio Fazio

Ewa Dembowski , Michael H Davidson

Alberto Lorenzatti , Peter P Toth

Sumanth Khadke , Jovana Vidovic , Vinod Patel

Ahmet Fuat, Jim Moore, Gary Ford, et al

Watch time: 1h 35m (4 videos)

Media

Nicolas M Van Mieghem, Joost Daemen

Watch time: 1h 35m 42s (16 videos)

Joost Daemen, Allen Jeremias, Ziad A Ali et al

Watch time: 55m 46s (1 video)

Lale Tokgözoğlu, Kausik Ray, Ulrich Laufs, et al

Watch time: 1h 23m 3s (5 videos)
ACC 23: Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study

Annapoorna Kini

Watch time: 8m 1s
ACC.23 Late-Breaker Discussion: The CLEAR-Outcomes Trial

Harriette Van Spall, Steven E Nissen

Watch time: 16m 12s
View from the Thoraxcenter: What's Hot at ACC.23?

Nicolas M Van Mieghem, Joost Daemen

Watch time: 22m 4s

Ahmet Fuat, Gary Ford, Kausik Ray, et al

Watch time: 1h 36m 11s
Radcliffe & CardioNerds @AHA22: Reduction of Lp(a) With Small Interfering RNA

Gurleen Kaur, Michelle O'Donoghue

Watch time: 14m 28s
Radcliffe & CardioNerds @AHA22: Reduction of Triglycerides With Pemafibrate

Aruna D Pradhan, Gurleen Kaur

Watch time: 14m 20s
FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano

Watch time: 2m 56s
FOURIER-OLE: The Trial in Context

Marc S Sabatine

Watch time: 3m 24s
FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

Michelle O'Donoghue

Watch time: 3m 30s

Media

Ahmet Fuat, Gary Ford, Kausik Ray, et al

Watch time: 1h 36m 11s

Maciej Banach, Yassir Javaid, Lale Tokgözoğlu, et al

Watch time: 1h 27m 1s
ACC.24: Olezarsen for Hypertriglyceridemia and ASCVD

Brian Bergmark

Watch time: 3m 40s
ESC 24: Day 4 Wrap-Up with Dr Alasnag and Dr Al-Shaibi

Mirvat Alasnag, Khaled Al-Shaibi

Watch time: 15m 45s
PURSUIT: AZD0780 in Patients With Dyslipidaemia

Matthew Roe

Watch time: 7m 7s
AHA 22: RESPECT EPA: Eicosapentaenoic Acid for Prevention of Coronary Artery Disease

Hiroyuki Daida, Saahil A Jumkhawala

Watch time: 14m 14s
ACC.24: The LIBerate-CVD Trial

Evan A Stein

Watch time: 7m 18s

Joost Daemen, Allen Jeremias, Ziad A Ali et al

Watch time: 55m 46s (1 video)
ACC 2020: Inclisiran Potently and Durably Reduces Ldl-c

R Scott Wright

Watch time: 13m 43s

Nina Barnett, Yassir Javaid, Paresh Parmar et al

Watch time: 18m 47s (4 videos)
ACC 23: MK-0616: Oral PCSK9 inhibitor In Hypercholesterolemia Patients

Christie Ballantyne

Watch time: 3m 44s
ACC 23: Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study

Annapoorna Kini

Watch time: 8m 1s

Articles

Interventional Cardiology for Coronary Artery Disease

Subha V Raman

,

Citation:

European Cardiovascular Disease 2006;2(1):1–3

DOI:

https://doi.org/10.15420/ecr.2006.1.1m
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 441
  • Downloads: Downloads 1

Magnetic Resonance Angiography Using the Intravascular Contrast Agent Vasovist

Mathias Goyen

,

Citation:

European Cardiovascular Disease 2006;2(1):1–4

DOI:

https://doi.org/10.15420/ecr.2006.1.1d
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 379
  • Downloads: Downloads 1

New Insights on Simvastatin and Ezetimibe in a Single Tablet

Alberto Corsini

,

Citation:

European Cardiovascular Disease 2007;3(1):12–5

DOI:

https://doi.org/10.15420/ecr.2007.0.1.12
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 1139
  • Downloads: Downloads 6

Overview to Antihypertensive and Lipid-lowering Therapies and Patient Care

Robert A Vogel

,

Citation:

US Cardiology 2006;3(2):18–9

DOI:

https://doi.org/10.15420/usc.2006.3.2.18
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 290
  • Downloads: Downloads 0